Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ODI Pharma ABXSAT:ODI +3.25%46 Operating Margin % is 2.44% as of Mar. 2026. GuruFocus rates XSAT:ODI with a GF Score™ of 46/100 and a GF Value™ of kr9.52 (Significantly Undervalued). Among 961 Drug Manufacturers companies, ODI Pharma AB ranks worse than 67.01% on this metric.
Operating Margin % is calculated as Operating Income divided by its Revenue. ODI Pharma AB's Operating Income for the
three
months ended in Mar. 2026 was kr0.31 Mil. ODI Pharma AB's Revenue for the
three
months ended in Mar. 2026 was kr12.71 Mil. Therefore, ODI Pharma AB's Operating Margin % for the quarter that ended in Mar. 2026 was 2.44%.
The historical rank and industry rank for ODI Pharma AB's Operating Margin % or its related term are showing as below:
XSAT:ODI'
s Operating Margin % Range Over the Past 10 Years
Min: -4900 Med: -1238.25 Max: 1.92
Current: 1.3
XSAT:ODI's Operating Margin % is ranked worse than 67.01% of 961
companies
in the Drug Manufacturers industry
Industry Median: 7.57
vs XSAT:ODI: 1.30
ODI Pharma AB's 5-Year Average Operating Margin % Growth Rate was 0.00% per year.
ODI Pharma AB's Operating Income for the
three
months ended in Mar. 2026 was kr0.31 Mil.
Its Operating Income for the trailing twelve months (TTM) ended in Mar. 2026 was kr0.39 Mil.
ODI Pharma AB (XSAT:ODI) Operating Margin % Explanation
Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.
Be Aware
Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).
If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.
For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokias Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).
Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.
ODI Pharma AB Operating Margin % Related Terms
ODI Pharma AB Operating Margin % Historical Data
* Premium members only.
The historical data trend for ODI Pharma AB's Operating Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XSAT:ODI vs ZTS, UTHR, VTRS: Operating Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, ODI Pharma AB's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ODI Pharma AB Operating Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, ODI Pharma AB's Operating Margin % distribution charts can be found below:
* The bar in red indicates where ODI Pharma AB's Operating Margin % falls into.
Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.
ODI Pharma AB's Operating Margin % for the fiscal year that ended in Jun. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ODI Pharma AB (XSAT:ODI) has a Operating Margin % of 2.44% as of Mar. 2026. Operating margin is the ratio of total operating income to net sales. View historical data on ODI Pharma AB and its competitors. According to the industry distribution chart, ODI Pharma AB ranks #644 out of 961 companies in the Drug Manufacturers industry, placing it in the top 67%.
Is ODI Pharma AB's Operating Margin % too high?
ODI Pharma AB's current Operating Margin % is 2.44%. The Drug Manufacturers industry median Operating Margin % is 7.57. ODI Pharma AB's value of 2.44% is 67.8% below this industry median. Based on the distribution chart, ODI Pharma AB ranks #644 out of 961 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, ODI Pharma AB has a GF Score™ of 46/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does ODI Pharma AB's Operating Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, ODI Pharma AB ranks #644 out of 961 companies for Operating Margin %. This places ODI Pharma AB in the lower half of its industry. The industry median Operating Margin % is 7.57. ODI Pharma AB's value of 2.44% is 67.8% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Operating Margin % for a Drug Manufacturers company?
The median Operating Margin % among Drug Manufacturers companies is 7.57, based on 961 companies in the industry. Companies in the top quartile (top 25%) have a Operating Margin % significantly above this median, while those in the bottom quartile fall well below. However, Operating Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. ODI Pharma AB's current Operating Margin % of 2.44% is 67.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Operating Margin % mean?
A high Operating Margin % can signal that a stock is expensive relative to its fundamentals. Operating margin is the ratio of total operating income to net sales. View historical data on ODI Pharma AB and its competitors. For the Drug Manufacturers industry, the median Operating Margin % is 7.57 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ODI Pharma AB's current Operating Margin % is 2.44%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ODI Pharma AB stock overvalued right now?
Based on GuruFocus' analysis, ODI Pharma AB (XSAT:ODI) is currently considered Significantly Undervalued. The stock's GF Value™ is kr9.52, compared to a current price of kr2.54 — trading 73.3% below its estimated fair value. The current Operating Margin % is 2.44% and 67.8% below the Drug Manufacturers industry median of 7.57. ODI Pharma AB's overall GF Score™ is 46/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Operating Margin % calculated?
Operating Margin % is calculated from a company's financial statements. For ODI Pharma AB (XSAT:ODI), the current Operating Margin % is 2.44% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is ODI Pharma AB (XSAT:ODI) Overvalued in 2026?
Based on GuruFocus' analysis, ODI Pharma AB stock appears to be undervalued.
The current stock price of kr2.54 is trading 73.3% below its estimated GF Value™ of kr9.52.
GuruFocus considers ODI Pharma AB to be Significantly Undervalued.
Key valuation signals for XSAT:ODI:
Operating Margin %: 2.44%
GF Value™: kr9.52 vs. price of kr2.54 (73.3% below fair value)
Industry Position: 67.8% below the Drug Manufacturers median (#644 of 961)
No single metric tells the full story. See the XSAT:ODI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSAT:ODI has been successfully added to your 
